February 14, 2020 News by Ana Pena PhD Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS First-line use of Genentech‘s Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights‘ report. However, the latest edition of “RealWorld Dynamix: DMT New Starts in Multiple Sclerosis (US),” based…
August 21, 2019 News by Ana Pena PhD Gilenya, Aubagio, Tysabri, Tecfidera Dominate MS Therapy Switches in Europe, Spherix Survey Finds Novartis‘ Gilenya (fingolimod), Sanofi Genzyme‘sĀ Aubagio (teriflunomide), andĀ BiogenāsĀ TysabriĀ (natalizumab) and Tecfidera (dimethyl fumarate) are the top disease-modifying therapies to which patients with multiple sclerosis (MS) have most frequently switched in…
July 2, 2019 News by Ana Pena PhD Neurologists Prefer Mayzent for SPMS and RRMS, But Mavenclad Could Be ‘Ideal’ First Switch, Report Suggests While neurologists favor Novartis‘ Mayzent (siponimod) for people with active secondary progressive multiple sclerosis (SPMS) and transitioning relapsing-remitting MS (RRMS), EMD Serono‘s Mavenclad (cladribine) could serve as a first option for patients with RRMS who failed initial therapy, Spherix Global Insights says in its…
December 15, 2017 News by Patricia Silva, PhD Ocrevus’ Use Continues Rising, with RRMS Patients Receiving the Most Attention U.S. neurologists are increasingly prescribing Genentech’s Ocrevus (ocrelizumab) to their multiple sclerosis patients, Spherix Global InsightsĀ reports. Another good sign for Genentech is that, in just three months, neurologists have increased by 50 percent their estimate of the numbers of relapsing-remitting MS patients who could benefit from Ocrevus.
August 1, 2017 Columns by Ed Tobias MS Docs Tell How They Choose Treatments What does your neurologist consider when he or she is deciding how best to treat your multiple sclerosis? A recent report from Spherix Global Insights, a business intelligence and market research company that looks at drug trends every quarter, sheds some light on that. In my…
July 28, 2017 Columns by Ed Tobias MS Therapies: What’s Hot, What’s Not Ocvevus (ocrelizumab) is off to a running start, Tecfidera (dimethyl fumarate) leads the pills and the four injectable multiple sclerosis drugs are being used by fewer MS patients. But Copaxone (glatiramer acetate injection) remains the leader of the pack of the disease-modifying therapies. Those are…
May 18, 2017 News by Patricia Silva, PhD Ocrevus Market Entry Already Changing Dynamics in MS Treatment Choices, Spherix Analysis Suggests Multiple sclerosis (MS) patients are largely moving away from injectable drugs and towards oral treatments when they switch from first to second-line MS therapies. ButĀ that might change with theĀ introduction of Ocrevus (ocrelizumab), whichĀ has becomeĀ the drug of choice for manyĀ neurologists advising patients on drug switches. The real-world analysis by…
October 13, 2016 News by Patricia Silva, PhD Neurologists Anticipate FDA Approval of Ocrevus as 1st Progressive MS Treatment, Survey Finds Neurologists in the U.S. expect ā or, at least, highly anticipate ā that Ocrevus (ocrelizumab), being developed by Roche as a treatment for both relapsing and progressiveĀ multiple sclerosis (MS), will be approved by year’s end, and a sizableĀ numberĀ plan on quickly prescribing it, according to a recent update byĀ Ā Spherix…